Meperidine (Demerol) Market Size to Reach $563.7 Million, Globally, by 2032 at 1.5% CAGR: Coherent Market Insights

/EIN News/ -- Burlingame, CA, April 21, 2025 (GLOBE NEWSWIRE) -- Coherent Market Insights published a report, titled, the global Meperidine (Demerol) Market size is estimated to grow from US$ 507.9 Million in 2025 and is forecast to reach a value of US$ 563.7 Million by 2032 at a CAGR of 1.5% between 2025 and 2032.

Request a Sample of the US Tariff Impact Analysis Report: https://www.coherentmarketinsights.com/insight/request-sample/3816

Global Meperidine (Demerol) Market Key Takeaways

The global meperidine (demerol) market size is anticipated to expand from USD 507.9 Mn in 2025 to USD 563.7 Mn by 2032. Global sales of meperidine (Demerol) will likely increase at a CAGR of 1.5% throughout the forecast period.

By form, tablets segment is projected to account for around USD 284.42 million in 2025. This can be attributed to patients’ preference for meperidine (Demerol) tablets, owing to their convenience, longer shelf life, and ease of storage.

Based on application, anesthesia segment is set to dominate the industry, accounting for a prominent meperidine (Demerol) market share in 2025.

In terms of distribution channel, retail pharmacies segment will likely generate higher market revenues during the forecast period.

North America is expected to remain the undisputed leader in the global meperidine (Demerol) market during the forecast period, owing to high number of surgeries performed and increasing consumption of opioids for pain management. As per Coherent Market Insights’ latest meperidine (Demerol) market analysis, North America is poised to account for around 1/2 of the global market share in 2025.

Asia Pacific remains the second-largest market for meperidine (Demerol), and the trend will likely persist through 2032. This is attributed to increasing prevalence of acute and chronic pain conditions and expanding access to pain management medications, especially across nations like India, China, and Japan.

Get Up to 25% Discount on the US Tariff Impact Analysis Report: https://www.coherentmarketinsights.com/insight/buy-now/3816

Increasing Chronic Pain Prevalence Spurring Sales Growth

A new report by Coherent Market Insights outlines significant meperidine (Demerol) market growth factors. One major factor expected to fuel growth of meperidine (Demerol) industry is the increasing prevalence of chronic pain globally.

According to the International Association for the Study of Pain, around 20% of the adult population globally suffers from chronic pain, making it a significant global health issue. To counter this, people use opioid pain management medications like meperidine.

Meperidine is commonly used for its potent analgesic effects in treating moderate to severe pain, especially in cases where other pain management strategies have proven insufficient. Thus, as the prevalence of chronic pain rises, so does the demand for meperidine (Demerol).

Side Effects and Use of Alternatives Limiting Market Growth

Meperidine (Demerol) usage is gradually declining in many countries due to its potential drug interactions, risk of neurotoxicity, and other safety concerns. Its usage can cause side effects like dizziness, nausea, vomiting, constipation, and breathing issues. These safety concerns are reducing overall meperidine (Demerol) market demand.

Many healthcare professionals and patients are shifting their preference towards safer and more effective alternatives like fentanyl or non-opioid analgesics. This shift is expected to restrain growth of the global meperidine (Demerol) market during the forecast period.

Rise in Surgical Procedures Population Creating Growth Prospects

Meperidine is commonly used for pain relief in surgical procedures. Thus, an increase in the number of surgeries, including minimally invasive ones, will likely fuel demand for analgesics like meperidine (Demerol).

Rising geriatric population is also expected to create growth opportunities for meperidine (Demerol) manufacturers. This is because older people are more susceptible to chronic pain conditions and often require pain management medications, including opioids like meperidine.

According to an article published in the National Library of Medicine, chronic pain affects a significant portion of the elderly population, with some studies indicating that up to 76% of older adults living in the community experience pain.

Opioids like meperidine are often used by elderly to manage discomfort and improve quality of life. Therefore, an increase in the elderly population with pain conditions is expected to boost meperidine (Demerol) sales during the forecast period.

Ask for Customization Report: https://www.coherentmarketinsights.com/insight/request-customization/3816

Emerging Meperidine (Demerol) Market Trends

Availability of cost-effective generic versions of meperidine is making it more accessible and affordable. This can drive its usage in regions and healthcare settings where cost is a significant factor.

Technological advancements in drug delivery systems are paving way for more efficient injectable formulations and administration methods. This can make meperidine a more convenient option for healthcare providers as well as patients.

Usage of meperidine (Demerol) for applications like cough relief and diarrhea treatment is also playing a key role in boosting the overall meperidine (demerol) market growth.

Leading companies are focusing on developing abuse-deterrent formulations of meperidine to address concerns regarding opioid abuse.

Analyst’s View

“The global meperidine (Demerol) market is set to witness sluggish growth, driven primarily by rising prevalence of acute and chronic pain conditions, increasing number of surgeries performed globally, and growing geriatric population,” said senior analyst Vipul Patil. “On the other hand, side effects associated with meperidine and transition towards safer alternatives are limited meperidine (Demerol) market growth.

Competitor Insights

Key companies listed in meperidine (Demerol) market report:

• Hikma Pharmaceuticals USA Inc.
• Pfizer, Inc.
• Vintage Pharmaceuticals, Inc.
• Epic Pharma, Inc.
• Boehringer Ingelheim
• Sanofi
• Egalet Corporation
• Janssen Pharmaceuticals
• Mallinckrodt Pharmaceuticals.
• Sun Pharmaceutical

Key Developments

In January 2023, Pfizer Inc. entered into an agreement with Abzena under which it will acquire Abzena’s manufacturing facility in Sanford, North Carolina. The new facility will improve Pfizer’s innovative pipeline products.

In April 2022, Hikma Pharmaceuticals completed acquisition of Custopharm Inc., enhancing its portfolio of drugs, including meperidine, and expanding its market reach.

Make Smarter Decisions – Buy the US Tariff Impact Analysis Report: https://www.coherentmarketinsights.com/insight/buy-now/3816

Detailed Segmentation:

By Form :

• Tablet
• Injection
• Syrup
  

By Application :

• Anesthesia
• Cough Treatment
• Diarrhea Treatment
  

By Distribution Channel :

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
  

By Region:

• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U,K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa

Transform your Strategy with Exclusive Trending Reports:

Inhalation Anesthesia Market is estimated to be valued at USD 1,483.6 Mn in 2025 and is expected to reach USD 2,129.7 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 5.3% from 2025 to 2032.

Global anesthesia endotracheal tube market is estimated to be valued at US$ 178.7 million in 2022 and is expected to exhibit a CAGR of 6.2% during the forecast period (2022-2030).

The global cold, cough, and sore throat remedies market is estimated to account for US$ 36,325.0 Mn in terms of value in 2019 and is expected to reach US$ 46,869.6 Mn by the end of 2027.

Cough Suppressant Drugs Market Analysis & Forecast 2032

Carcinoid Syndrome Diarrhea Treatment Market Analysis & Forecast: 2025-2032

About Us:

Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

Follow Us: LinkedIn | Twitter